

DIASORIN INCREASES DIAGNOSTIC TEST MENU FOR MOLECULAR SCREENING OF ACUTE MYELOID LEUKEMIA

Early stratification of patient risk through effective screening will facilitate timely and effective implementation of therapy leading to improved patient management.

July 14, 2016 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap: DIA) launches a new CE-IVD molecular diagnostic test, **lam AML1-ETO** (*not available in the USA*) for the identification of the **one of the most common genetic causes of Acute Myeloid Leukemia**.

The new test allows reliable, easy and extremely fast (*11 minutes instead of nearly 4 hours*) **detection of the AML1-ETO translocation**, which is one of the most common genetic causes of **“Acute Myeloid Leukemia”**.

Whilst this translocation is associated with a good prognosis, poor risk stratification results in less than 50% of patients reaching a complete remission. Rapid molecular identification of the translocation is therefore crucial for therapeutic decision making.

Identification of risk groups, in a timely and reliable manner, by genetic means represents a unique opportunity for implementing effective therapy. This is especially important in older patient populations who may not be eligible for bone marrow transplantation.

The short time taken to complete the DiaSorin test will provide medical staff with key information to initiate the correct treatment for their patients.

The **lam AML1-ETO** will represent the optimal solution for reliable, rapid and simple **molecular screening of AML at diagnosis**.

Paul Eros, Vice President of International Marketing for DiaSorin Molecular, commented: *“With the launch of this assay DiaSorin shows its commitment to providing innovative molecular solutions to aid in clinical decision making”* he went on to add *“That this third assays, following the earlier launches of lam BCR-ABL and lam PML-RARA, has been made possible as a result of very strong collaboration in research and development between DiaSorin and key opinion leaders in the field of hematological malignancy”*.



REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	AML1 - ETO	
Diagnosis	Acute Myeloid Leukemia	
Platform	Immunodiagnosics	Molecular Diagnostics
	LIAISON XL	LIAISON IXT
	LIAISON	LIAISON IAM
Clinical area	Infectious Diseases	Infectious Disease
	Hepatitis & Retrovirus	
	Oncology & Endocrinology	Onco-Haematology
	Bone & Mineral	
	Cardiac Markers	
GI Stool Testing		

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Senior Director
Tel. +39.0161.487.988
riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator
Tel. +39.0161.487.567
ines.diterlizzi@diasorin.it

About DiaSorin:

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For more information, visit www.diasorin.com